Pfizer
PFE
$25.08
-0.52%
Pfizer Inc. is a global pharmaceutical giant operating in the Drug Manufacturers - General industry, with a core business focused on developing, manufacturing, and commercializing prescription drugs and vaccines, including major products like Prevnar 13, Vyndaqel, and Eliquis. The company is a dominant market leader with a vast global footprint, historically distinguished by its scale, extensive R&D pipeline, and blockbuster portfolio. The current investor narrative is dominated by the company's challenging post-pandemic transition, characterized by a steep revenue decline from its COVID-19 products, ongoing patent expirations for key drugs, and a high-stakes pivot to reignite growth through new launches and strategic acquisitions, while simultaneously managing investor confidence in its dividend and executing a leadership transition.…
PFE
Pfizer
$25.08
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating & Thesis: Hold. Pfizer is a high-yield, deep-value turnaround story with significant execution risk; the current price reflects substantial pessimism, but visible catalysts for a re-rating are not yet imminent. The analyst consensus, implied by an average EPS target of $2.39 and a forward P/E of 8.91x, suggests a target near $21.31, indicating potential downside, underscoring the cautious stance.
Supporting Evidence: The primary valuation metric, a forward P/E of 8.91x, is exceptionally low and prices in a severe earnings trough. However, revenue is currently declining (-1.16% YoY in Q4), and profitability is highly volatile, with a trailing net margin of 12.42%. The 6.9% dividend yield is supported by strong TTM free cash flow of $9.08 billion, providing a defensive floor. The stock trades at a Price-to-Sales ratio of 2.26x and an EV/EBITDA of 13.76x, which are reasonable for a large-cap pharma but do not signal deep undervaluation relative to peers.
Risks & Conditions: The two biggest risks are continued revenue erosion from the patent cliff and further earnings volatility from restructuring charges. This Hold rating would upgrade to a Buy if the forward P/E compressed further towards 8x alongside concrete evidence of pipeline success (e.g., positive Phase 3 data for berobenatide) and a return to stable, non-COVID revenue growth. It would downgrade to a Sell if the dividend coverage weakened (FCF yield falling below dividend yield) or if the stock broke below its 52-week low of $23.11 on worsening fundamentals. The stock is fairly valued to slightly undervalued relative to its own depressed history but remains a 'show me' story.
Sign up to view all
PFE 12-Month Price Forecast
The investment case for Pfizer hinges on a successful transition from a post-COVID, patent-cliff narrative to a pipeline-driven growth story, which is far from certain. The low forward multiple and high yield provide a margin of safety for patient, income-oriented investors, but the lack of near-term revenue growth and technical weakness warrant caution. The stance would upgrade to bullish on confirmation of pipeline success and a return to organic growth, or downgrade to bearish on a dividend cut or sustained breakdown below $23 support. For now, the stock is a 'watch and wait' holding.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $32.60 and implied upside of +30.0% versus the current price.
Average Target
$32.60
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$20 - $33
Analyst target range
Pfizer is covered by 11 analysts, and the consensus sentiment appears mixed but leans cautiously optimistic, with recent institutional actions including several 'Buy' ratings from firms like Guggenheim and HSBC, an upgrade from Argus Research, and maintained 'Neutral' or 'Equal Weight' ratings from others. The average target price implied by the analyst data is calculated from the estimated EPS average of $2.39 and the forward PE of 8.91x, resulting in a target of approximately $21.31, which would imply a downside of about 15% from the current price of $25.21, though a more precise consensus target price is not directly provided in the dataset. The target range, derived from estimated EPS, suggests a low target around $20.25 (using the low EPS estimate of $2.27) and a high target around $22.27 (using the high EPS estimate of $2.50); the high target assumes successful execution of the growth pipeline and margin stability, while the low target likely factors in continued revenue erosion and competitive pressures. The recent pattern of analyst actions shows a balance between upgrades and reaffirmations, indicating ongoing debate but not a broad wave of downgrades, and the relatively tight range between low and high EPS estimates signals moderate consensus on near-term earnings potential.
Bulls vs Bears: PFE Investment Factors
The evidence currently favors the bear case, as fundamental headwinds from revenue decline and earnings volatility are manifesting in sustained technical underperformance and negative market sentiment. The most important tension in the investment debate is the race between Pfizer's promising pipeline (e.g., obesity drug berobenatide) and the accelerating revenue erosion from its patent cliff. If new launches gain traction faster than expected, the deep value represented by the 8.91x forward P/E could be realized, but if execution stumbles, the stock's defensive dividend may be its only support amidst further multiple compression.
Bullish
- Strong Free Cash Flow Supports Dividend: Pfizer generates robust free cash flow of $9.08 billion (TTM), which provides ample coverage for its dividend. This cash generation underpins the attractive 6.9% dividend yield, offering a defensive income stream while the company navigates its transition.
- Deep Value with Low Forward P/E: The stock trades at a forward P/E of 8.91x, a significant discount to its trailing P/E of 18.21x and indicating market expectations for an earnings recovery. This low multiple suggests substantial pessimism is priced in, creating a potential value opportunity if new product launches succeed.
- Healthy Balance Sheet with Manageable Debt: Pfizer maintains a solid financial foundation with a debt-to-equity ratio of 0.78, which is manageable for a large-cap pharmaceutical company. This provides strategic flexibility for potential acquisitions or continued R&D investment without over-leveraging.
- Promising Pipeline Catalysts Emerging: Recent Phase 2b data for the obesity drug berobenatide showed 16% weight loss, positioning it as a credible competitor in a high-growth market. Successful pipeline execution, particularly in obesity and oncology, is critical to offsetting patent expirations.
Bearish
- Sustained Revenue Decline and Patent Cliff: Q4 2025 revenue declined 1.16% YoY to $17.56 billion, reflecting the ongoing post-COVID normalization and pressure from patent expirations on key drugs. The company's core challenge is replacing this lost revenue before the decline accelerates.
- Extreme Earnings Volatility and Margin Pressure: Recent quarterly results show severe inconsistency, with Q4 2025 net income at -$1.65 billion versus +$3.54 billion in Q3, driven by one-time charges and mix shifts. This volatility, alongside a gross margin that fell from 74.95% to 69.97% between those quarters, complicates forecasting and erodes investor confidence.
- Persistent Technical Downtrend and Underperformance: The stock is in a clear downtrend, underperforming the SPY by 21.67 percentage points over the past three months and trading near the lower end of its 52-week range ($23.11-$28.75). This persistent negative momentum reflects deep-seated bearish sentiment and a lack of catalysts to reverse the trend.
- Leadership Transition Adds Execution Risk: Recent news highlights investor anxiety over a CFO transition, testing confidence in the execution of critical 2026 financial targets. Leadership uncertainty during a pivotal turnaround phase increases operational and strategic risk.
PFE Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of only 5.57% as of the data date, which significantly underperforms the SPY's 24.99% gain over the same period. Currently trading at $25.21, the price sits near the lower end of its 52-week range ($23.11 to $28.75), at approximately 20% above the 52-week low, indicating the stock is in a value zone but remains under significant selling pressure and has failed to sustain momentum. Recent momentum is decisively negative, with the stock down 1.75% over the past month and down 6.53% over the past three months, a sharp deceleration and reversal from its modest positive 1-year trend, signaling a breakdown and heightened bearish sentiment as the stock underperforms the market by wide margins (relative strength of -21.67 over 3 months). Key technical support is clearly defined at the 52-week low of $23.11, while resistance lies at the 52-week high of $28.75; a breakdown below $23.11 would likely trigger further technical selling, while a sustained move above $28.75 is needed to signal a meaningful trend reversal. The stock's low beta of 0.295 indicates it is approximately 70% less volatile than the broader market, which historically provided defensive characteristics but currently suggests it is being treated as a low-growth, income-oriented holding amid its fundamental challenges.
Beta
0.29
0.29x market volatility
Max Drawdown
-12.2%
Largest decline past year
52-Week Range
$23-$29
Price range past year
Annual Return
+4.6%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | -0.2% |
| 3m | -7.0% | +14.0% |
| 6m | +0.2% | +7.8% |
| 1y | +4.6% | +25.3% |
| ytd | -0.4% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory is currently declining, with Q4 2025 revenue of $17.56 billion representing a year-over-year contraction of 1.16%. This follows a volatile multi-quarter trend where revenue peaked during the pandemic and has since normalized, with the core challenge being the sharp drop in COVID-related product sales and pressure from patent expirations, indicating the company is in a transitional phase seeking new growth drivers. Profitability is highly inconsistent, as evidenced by a net income of -$1.65 billion and a gross margin of 69.97% in the most recent quarter, contrasting sharply with a net income of $3.54 billion and a gross margin of 74.95% in the prior Q3; this quarterly volatility, driven by large one-time charges and revenue mix shifts, complicates the assessment of underlying operational margin trends, though the trailing twelve-month net margin stands at 12.42%. The balance sheet is relatively healthy with a manageable debt-to-equity ratio of 0.78, and the company generates substantial cash flow, with free cash flow (TTM) of $9.08 billion providing strong coverage for its dividend; however, the current ratio of 1.16 indicates adequate but not robust short-term liquidity, and the return on equity of 8.99% reflects modest efficiency in generating profits from shareholder equity.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given the company's positive trailing twelve-month net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. Pfizer's trailing PE ratio is 18.21x, while its forward PE is significantly lower at 8.91x, indicating the market expects a substantial recovery in earnings over the next year, likely pricing in the trough of the post-COVID earnings decline and potential contributions from new product launches. Compared to sector averages, Pfizer's trailing PE of 18.21x is at a discount to the broader market but appears reasonable for a large-cap pharma; its Price-to-Sales ratio of 2.26x and EV/EBITDA of 13.76x suggest the market is valuing the company based on its current earnings power and cash flow generation rather than high growth expectations. Historically, the current trailing PE of 18.21x is below the stock's own historical range seen in recent years, which has included periods of much higher multiples during peak COVID earnings and deeply negative multiples during quarters with large write-offs; this positioning near the lower end of its historical band suggests the market has priced in significant pessimism, potentially offering a value opportunity if the company can successfully execute its growth transition.
PE
18.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Pfizer faces significant earnings volatility, as evidenced by a Q4 2025 net loss of -$1.65 billion following a $3.54 billion profit in Q3, driven by large one-time charges and revenue mix instability. This complicates the assessment of sustainable profitability. Furthermore, the company is in the midst of a patent cliff, with key drug revenues declining, and must rely on new product launches to stabilize its top line, which carries high execution risk. While the dividend appears safe with strong free cash flow coverage, a payout ratio of 125.8% (TTM) indicates it is not fully covered by trailing net income, introducing vulnerability if cash generation weakens.
Market & Competitive Risks: The stock's low beta of 0.295 indicates it is treated as a defensive, low-growth holding, which exposes it to valuation compression if growth expectations fail to materialize. Competitively, recent news shows Merck securing an FDA label expansion for its pneumococcal vaccine, directly challenging Pfizer's Prevnar franchise, while Eli Lilly and Novo Nordisk dominate the obesity market Pfizer is attempting to enter. Regulatory and clinical trial setbacks for pipeline assets like berobenatide could further delay the growth pivot and prolong investor pessimism.
Worst-Case Scenario: The worst-case scenario involves a failure of key pipeline candidates (e.g., berobenatide), accelerated market share loss for core products like Prevnar, and a deeper-than-expected post-COVID revenue decline. This could trigger a dividend cut if free cash flow deteriorates, leading to a wholesale derating of the stock. The realistic downside could see the stock re-testing and breaking its 52-week low of $23.11, representing a potential loss of approximately -8% from the current price of ~$25.21, with further declines possible if sentiment turns decisively negative.
FAQ
The key risks are: 1) Financial/Operational: Continued revenue erosion from the patent cliff and extreme quarterly earnings volatility, as seen in the swing from a $3.54B profit to a -$1.65B loss in consecutive quarters. 2) Competitive: Intense competition in core vaccines (e.g., from Merck) and as a late entrant in obesity drugs. 3) Execution: Failure of the R&D pipeline to deliver sufficient new products to offset declining legacy sales. 4) Sentiment: Persistent technical downtrend and underperformance versus the market, which could lead to further multiple compression.
The 12-month forecast presents three scenarios. The base case (60% probability) sees the stock range-bound between $23.50 and $26.50, as the company navigates its transition without major breakthroughs or failures. The bull case (25% probability) targets a return to the 52-week high of $28.75 and beyond on successful pipeline execution. The bear case (15% probability) envisions a drop towards the $21-$23 range if execution falters. The base case is most likely, assuming the current challenging fundamentals persist but do not significantly worsen.
Based on forward earnings, PFE appears deeply undervalued, trading at a forward P/E of 8.91x, which is a steep discount to its own trailing P/E of 18.21x and suggests the market expects severely depressed future earnings. However, this low multiple is justified by the current reality of revenue decline (-1.16% YoY) and high earnings volatility. The valuation implies the market is paying a fair price for a company in transition with significant challenges, not a premium for growth. It is undervalued only if the turnaround succeeds.
PFE is a contentious buy. For income-seeking value investors, the 6.9% yield and low 8.91x forward P/E offer an attractive margin of safety and pay-for-waiting scenario. However, for growth-oriented investors, it is not a good buy due to its declining revenue, earnings volatility, and significant execution risk related to its patent cliff and pipeline. The stock is best considered a speculative turnaround play within a diversified income portfolio, not a core growth holding.
PFE is unsuitable for short-term trading due to its low beta (0.295) and lack of near-term momentum catalysts; its recent 3-month performance of -6.53% underscores this. It is primarily a long-term, income-oriented investment for investors willing to hold for 3-5 years to see if the pipeline-driven turnaround materializes while collecting the dividend. The high yield and value characteristics are tailored for a patient, long-term holder, not a short-term trader seeking volatility or rapid growth.